Who makes Topical Gutt Nepafenac 0.1%?

Topical Gutt Nepafenac 0.1% is developed by Universiti Sains Malaysia.

What development phase is Topical Gutt Nepafenac 0.1% in?

Topical Gutt Nepafenac 0.1% is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Topical Gutt Nepafenac 0.1%

Universiti Sains Malaysia · FDA-approved active Small molecule Quality 2/100

Topical Gutt Nepafenac 0.1% is a marketed ophthalmic drug developed by Universiti Sains Malaysia, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and protected intellectual property, providing a competitive edge until the patent expiry. The primary risk is the potential for increased competition post-2028, as generic versions may enter the market.

At a glance

Generic name	Topical Gutt Nepafenac 0.1%
Also known as	Nevanac
Sponsor	Universiti Sains Malaysia
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Topical Nepafenac as Supplement for Diabetic Macular Edema (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Topical Gutt Nepafenac 0.1% CI brief — competitive landscape report
Topical Gutt Nepafenac 0.1% updates RSS · CI watch RSS
Universiti Sains Malaysia portfolio CI